ARUP's Laboratory Test Directory

Plasminogen Activator Inhibitor-1, PAI-1 (SERPINE1) Genotyping : 2004980
[ image for: Patient History For Molecular Genetic Testing]
Patient History For Molecular Genetic Testing
  


Mnemonic: PAI-1 GENO

Methodology: Polymerase Chain Reaction/Fluorescence Monitoring
Performed: Mon, Thu
Reported: 7-10 days
Specimen Required: Collect: Lavender (EDTA), pink (K2EDTA), or yellow (ACD Solution A or B).

Specimen Preparation: Transport 3 mL whole blood. (Min: 1 mL)

Storage/Transport Temperature: Refrigerated.

Stability (collection to initiation of testing): Ambient: 72 hours; Refrigerated: 1 week; Frozen: Unacceptable

Reference Interval:
By report
Interpretive Data: Background Information: Plasminogen Activator Inhibitor-1, PAI-1 (SERPINE1) Genotyping:
Characteristics:
The 4G allele within in the promoter region of the PAI-1 (SERPINE1) gene is associated with higher plasma PAI-1 activity when compared with the 5G allele. Heterozygosity or homozygosity for the 4G allele confers a risk for venous thromboembolism (VTE), especially in individuals with other thrombophilic risk factors, as well as a risk for myocardial infarction.
Frequency of the 4G Allele:
Caucasian 0.52, Hispanic 0.38, African-American 0.13-0.28.
Inheritance:
Autosomal dominant.
Clinical sensitivity:
Unknown.
Methodology:
Polymerase chain reaction and fluorescence monitoring.
Analytical Sensitivity and Specificity:
99 percent.
Limitations:
Variants in the PAI-1 (SERPINE1) gene, other than the 4G/5G polymorphism, are not evaluated. Rare diagnostic errors may occur due to primer and probe site mutations.

This test is performed pursuant to an agreement with Roche Molecular Systems, Inc.



Counseling and informed consent are recommended for genetic testing. Consent forms are available online at www.aruplab.com.

Refer to Statement C under Testing Information at http://www.aruplab.com.
CPT Code(s): 83891 Isolation; 83898 Amplification; 83896 x2 Nucleic acid probes; 83912 Interpretation and report - Additional CPT code modifiers may be required for procedures performed to test for oncologic or inherited disorders.
Cross References: FACV (Plasminogen Activator Inhibitor-1, PAI-1 (SERPINE1) Genotyping) , PAI (Plasminogen Activator Inhibitor-1, PAI-1 (SERPINE1) Genotyping) , PAI-1 (Plasminogen Activator Inhibitor-1, PAI-1 (SERPINE1) Genotyping) , Plasminogen Activator (Plasminogen Activator Inhibitor-1, PAI-1 (SERPINE1) Genotyping) , PT PCR (Plasminogen Activator Inhibitor-1, PAI-1 (SERPINE1) Genotyping) , SERPINE1 (Plasminogen Activator Inhibitor-1, PAI-1 (SERPINE1) Genotyping) , Thrombotic risk panel (Plasminogen Activator Inhibitor-1, PAI-1 (SERPINE1) Genotyping)
 
 

 

 

 
All ARUP Sites:        www.aruplab.com     ·     www.arupconsult.com     ·     www.arup.utah.edu     ·     www.childx.org     ·     www.utahblood.org